{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=11", "query": { "intervention": "Gleevec", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 351, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T14:15:36.902Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00237185", "title": "A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)" ], "interventions": [ { "name": "Imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2000-06", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-08-19", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00237185" }, { "nct_id": "NCT01117987", "title": "Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2010-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117987" }, { "nct_id": "NCT01660906", "title": "Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Phase Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2012-12", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 5, "location_summary": "Anaheim, California • Southington, Connecticut • Baltimore, Maryland + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Sylvania", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660906" }, { "nct_id": "NCT00470470", "title": "Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Malignant Melanoma", "Recurrent Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 8, "location_summary": "Los Angeles, California • Miami Beach, Florida • West Palm Beach, Florida + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470470" }, { "nct_id": "NCT05743465", "title": "A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia" ], "interventions": [ { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1769, "start_date": "2021-10-06", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743465" }, { "nct_id": "NCT01383447", "title": "Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2010-10", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-08-08", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383447" }, { "nct_id": "NCT00025415", "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Undifferentiated Leukemia", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Eosinophilic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Gastrointestinal Stromal Tumor", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Meningeal Chronic Myelogenous Leukemia", "Monoclonal Gammopathy of Undetermined Significance", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Polycythemia Vera", "Previously Treated Myelodysplastic Syndromes", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Hairy Cell Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 60, "start_date": "2001-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025415" }, { "nct_id": "NCT00036751", "title": "Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer", "Stage III Ovarian Epithelial Cancer", "Stage IV Ovarian Epithelial Cancer" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 40, "start_date": "2002-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036751" }, { "nct_id": "NCT01120821", "title": "Treatment of Polycythemia Vera With Gleevec", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycythemia Vera" ], "interventions": [ { "name": "Gleevec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2002-08", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2010-05-17", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01120821" }, { "nct_id": "NCT00585221", "title": "Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Cancer Brain", "Solid Tumors" ], "interventions": [ { "name": "Peginterferon-alpha 2b (PegIFNa2b);", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2007-07", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-10-20T14:15:36.902Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585221" } ] }